证 券 研 究 报 告 上 市 公 司 公 司 研 究 / 公 司 点 评 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2026 年 03 月 20 日 | | --- | --- | | 收盘价（元） | 128.88 | | 一年内最高/最低（元） | 202.88/128.86 | | 一年内最高/最低（元） | 202.88/128.86 | | --- | --- | | 市净率 | 5.1 | | 股息率%（分红/股价） | 3.88 | | 流通 A 股市值（百万元） | 26,350 | | 上证指数/深证成指 | 3,957.05/13,866.20 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 12 月 31 日 | | --- | --- | | 每股净资产（元） | 25.06 | | 资产负债率% | 8.35 | | 总股本/流通 A 股（百万） | 303/204 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： -40% -20% 0% 20% 40% 03-20 04-20 05- ...

上 市 公 司 | 一年内最高/最低（元） | 202.88/128.86 | | --- | --- | | 市净率 | 5.1 | | 股息率%（分红/股价） | 3.88 | | 流通 A 股市值（百万元） | 26,350 | | 上证指数/深证成指 | 3,957.05/13,866.20 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 12 月 31 日 | | --- | --- | | 每股净资产（元） | 25.06 | | 资产负债率% | 8.35 | | 总股本/流通 A 股（百万） | 303/204 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： -40% -20% 0% 20% 40% 03-20 04-20 05-20 06-20 07-20 08-20 09-20 10-20 11-20 12-20 01-20 02-20 03-20 爱美客 沪深300指数 (收益率) 相关研究 证券分析师 公 司 研 究 / 公 司 点 评 证 券 研 究 报 告 报告原因：有业绩公布需要点评 买入（维持） | 市 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4][6][10]. Core Insights - The company achieved a revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, up 5.33% year-on-year [1][4]. - The acquisition of REGEN Biotech for 190 million USD is a strategic move to enhance the company's competitive edge and international presence in the aesthetic medicine market [2][3]. - The company has a robust pipeline of products, with several expected to launch soon, indicating strong growth potential in the medium to long term [3][4]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2024 Revenue: 3.026 billion yuan, 2025 Revenue: 3.390 billion yuan (12.0% growth), 2026 Revenue: 3.911 billion yuan (15.4% growth), 2027 Revenue: 4.777 billion yuan (22.1% growth) [4][6]. - 2024 Net Profit: 1.958 billion yuan, 2025 Net Profit: 2.198 billion yuan (12.3% growth), 2026 Net Profit: 2.567 billion yuan (16.8% growth), 2027 Net Profit: 3.168 billion yuan (23.4% growth) [4][6]. - **Valuation Metrics**: - PE ratios for 2025, 2026, and 2027 are projected at 26X, 22X, and 18X respectively [4][6]. - The company’s net profit margin for 2024 is 64.66%, with a slight increase expected in subsequent years [1][6].